Combination of chemotherapy and immune checkpoint therapy by the immunoconjugates-based nanocomplexes synergistically improves therapeutic efficacy in SCLC

Combination of chemotherapy and immune checkpoint therapy by the immunoconjugates-based nanocomplexes synergistically improves therapeutic efficacy in SCLC

Although the etoposide and carboplatin (EP) combination strategy has been the first-line chemotherapy, patients with extensive-stage disease small-cell lung cancer (SCLC) still have poor survival outcomes. Our retrospective analysis revealed that 46 patients with SCLC only achieved medium overall su...

Full description

Bibliographic Details
Main Authors: Zhang Tao, Xingwang Kuai, Guangwei Wang, Sanfeng Liu, Kai Liu, Heng Zhang, Shujing Xia, Hua Zhu
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:Drug Delivery
Subjects:
Small-cell lung cancer
etoposide
carboplatin
immune checkpoint blocker
TPP1 peptide
nanocomplex
Online Access:https://www.tandfonline.com/doi/10.1080/10717544.2022.2039803

Internet

https://www.tandfonline.com/doi/10.1080/10717544.2022.2039803

Similar Items